ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO435

Genes Related to the Different Stages of Diabetic Kidney Disease: A Clariom™ D Assay in Patients with Biopsy Proven Diabetic Nephropathy

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical

Authors

  • Duan, Suyan, The First Affiliated Hospital of Nanjing Medical University, Nanjing, JIangSu, China
  • Zhang, Bo, The first affiliated hosptial of Nanjing Medical University, Nanjing, China
  • Yuan, Yanggang, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Background

Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease. A great number of metabolites, cytokines, proteins and transcription factors play a role in the accumulation of extracellular matrix and mesangial proliferation in the glomerulus. The integrative analysis of the proteomic and transcriptomic features of bioptic samples among different categories of patients affected by diabetic nephropathy, especially based on the accurate classification of the histopathological changes in the glomerular and tubulointerstitial compartment, could lead to the identification of new early biomarkers.

Methods

Microarray data obtained from glomeruli isolated from normal kidneys (n = 2) and kidneys from patients with DN (n = 4) were used for the Clariom™ D Assay.

Results

Two patients were diagnosed as type IIb stage DN with moderate proteinuria, while other two patients were diagnosed as type IV stage DN with massive proteinuria. In the present study, differentially expressed genes (DEGs) between healthy controls and patients with different stages of DN were also analyzed. To investigate the function changes in the course of DN progression, GO enrichment and KEGG pathway analyses were performed for both up- and down-regulated DEGs. GO provides 3 structured networks of de ned terms to describe gene product attributes: cellular compartment (CC), biological process (BP) and molecular function (MF). Results show that signaling pathways are altered by the up-regulated DEGs (Fig1,2).

Conclusion

In conclusion, our transcriptome based analysis suggests that the association between gene expression and renal pathology is mediated by structural changes and that there may be differences in pathways that lead to protenuria.

GO term